scholarly journals Stem Cell Therapy for Treatment of Stress Urinary Incontinence: The Current Status and Challenges

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Shukui Zhou ◽  
Kaile Zhang ◽  
Anthony Atala ◽  
Oula Khoury ◽  
Sean V. Murphy ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Urinary Incontinence ◽  
Stem Cell ◽  
Stress Urinary Incontinence ◽  
Cell Types ◽  
Current Status ◽  
Urinary System ◽  
Urethral Sphincter ◽  
Critical Problem ◽  
System Disease

Stress urinary incontinence (SUI) is a common urinary system disease that mostly affects women. Current treatments still do not solve the critical problem of urethral sphincter dysfunction. In recent years, there have been major developments in techniques to obtain, culture, and characterize autologous stem cells as well as many studies describing their applications for the treatment of SUI. In this paper, we review recent publications and clinical trials investigating the applications of several stem cell types as potential treatments for SUI and the underlying challenges of such therapy.

scholarly journals Minimally Invasive Therapies for Female Stress Urinary Incontinence: the Current Status of Bioinjectables/New Devices (Adjustable Continence Therapy, Urethral Submucosal Collagen Denaturation by Radiofrequency)

2009 ◽  
Vol 9 ◽  
pp. 466-478 ◽  
Author(s):  
Simone Crivellaro ◽  
John J. Smith
Keyword(s):  
Clinical Trials ◽  
Urinary Incontinence ◽  
Clinical Practice ◽  
Stress Urinary Incontinence ◽  
Minimally Invasive ◽  
Emerging Technologies ◽  
Current Status ◽  
Female Stress Urinary Incontinence ◽  
Salvage Procedure ◽  
Collagen Denaturation

The aim of this review is to provide an update on the current status of evolving minimally invasive therapies for stress urinary incontinence. Bioinjectables have been available for some time and their current status is reviewed. The adjustable continence device has been used as a salvage procedure for females for a number of years in clinical trials, yet many are unfamiliar with it. Lastly, radiofrequency via a transurethral route has also been utilized in small numbers and will be updated. These later two emerging technologies need further exposure to better define their role in our clinical practice.

scholarly journals Stem cell applications in regenerative medicine for stress urinary incontinence: A review of effectiveness based on clinical trials

2020 ◽  
Vol 18 (3) ◽  
pp. 194-205
Author(s):  
Bara Barakat ◽  
Knut Franke ◽  
Samer Schakaki ◽  
Sameh Hijazi ◽  
Viktoria Hasselhof ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Urinary Incontinence ◽  
Stem Cell ◽  
Stress Urinary Incontinence ◽  
Regenerative Medicine

scholarly journals Cell Therapy Clinical Trials for Stress Urinary Incontinence: Current Status and Perspectives

2018 ◽  
Vol 15 (3) ◽  
pp. 195-204 ◽  
Author(s):  
Isabel María Aragón ◽  
Bernardo Herrera Imbroda ◽  
María Fernanda Lara
Keyword(s):  
Clinical Trials ◽  
Urinary Incontinence ◽  
Stress Urinary Incontinence ◽  
Cell Therapy ◽  
Current Status

Types of Stem Cells Used in US-Based Clinical Trials between 1999 and 2014

2021 ◽  
Vol 26 ◽  
pp. 169-191
Author(s):  
Emma E. Redfield ◽  
Erin K. Luciano ◽  
Monica J. Sewell ◽  
Lucas A. Mitzel ◽  
Isaac J. Sanford ◽  
...  
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Stem Cell ◽  
Embryonic Stem Cells ◽  
Adult Stem Cells ◽  
Embryonic Stem ◽  
Cell Types ◽  
The Us ◽  
Health Database ◽  
Induced Pluripotent

This study looks at the number of clinical trials involving specific stem cell types. To our knowledge, this has never been done before. Stem cell clinical trials that were conducted at locations in the US and registered on the National Institutes of Health database at ‘clinicaltrials.gov’ were categorized according to the type of stem cell used (adult, cancer, embryonic, perinatal, or induced pluripotent) and the year that the trial was registered. From 1999 to 2014, there were 2,357 US stem cell clinical trials registered on ‘clinicaltrials.gov,’ and 89 percent were from adult stem cells and only 0.12 percent were from embryonic stem cells. This study concludes that embryonic stem cells should no longer be used for clinical study because of their irrelevance, moral questions, and induced pluripotent stem cells.

Stem Cells and Tissue Engineering Techniques

2013 ◽  
Vol 80 (1) ◽  
pp. 11-19
Author(s):  
Gigliola Sica
Keyword(s):  
Tissue Engineering ◽  
Stem Cells ◽  
Clinical Trials ◽  
Stem Cell ◽  
Urinary Tract ◽  
Animal Models ◽  
Embryonic Stem ◽  
Cell Types ◽  
Ethical Concerns ◽  
Neoplastic Lesions

The therapeutic use of stem cells and tissue engineering techniques are emerging in urology. Here, stem cell types, their differentiating potential and fundamental characteristics are illustrated. The cancer stem cell hypothesis is reported with reference to the role played by stem cells in the origin, development and progression of neoplastic lesions. In addition, recent reports of results obtained with stem cells alone or seeded in scaffolds to overcome problems of damaged urinary tract tissue are summarized. Among others, the application of these biotechnologies in urinary bladder, and urethra are delineated. Nevertheless, apart from the ethical concerns raised from the use of embryonic stem cells, a lot of questions need to be solved concerning the biology of stem cells before their widespread use in clinical trials. Further investigation is also required in tissue engineering utilizing animal models.

scholarly journals Revisiting Stem Cell-Based Clinical Trials for Ischemic Stroke

2020 ◽  
Vol 12 ◽  
Author(s):  
Joy Q. He ◽  
Eric S. Sussman ◽  
Gary K. Steinberg
Keyword(s):  
Clinical Trials ◽  
Stem Cell ◽  
Ischemic Stroke ◽  
Cell Types ◽  
Complex Problem ◽  
Review Article ◽  
Ischemic Brain ◽  
Cell Lineages ◽  
Ischemic Brain Tissue

Stroke is the leading cause of serious long-term disability, significantly reducing mobility in almost half of the affected patients aged 65 years and older. There are currently no proven neurorestorative treatments for chronic stroke. To address the complex problem of restoring function in ischemic brain tissue, stem cell transplantation-based therapies have emerged as potential restorative therapies. Aligning with the major cell types found within the ischemic brain, stem-cell-based clinical trials for ischemic stroke have fallen under three broad cell lineages: hematopoietic, mesenchymal, and neural. In this review article, we will discuss the scientific rationale for transplanting cells from each of these lineages and provide an overview of published and ongoing trials using this framework.

Sign in / Sign up

Export Citation Format

Share Document